Increased Platelet Adhesiveness in Patients with Venous Thromboembolic Disease

TH Open. 2024 Nov 30;8(4):e329-e339. doi: 10.1055/s-0044-1800798. eCollection 2024 Oct.

Abstract

Background Association between global platelet function and the risk of venous thromboembolic disease (VTE) has been proposed, though the mechanisms do not involve increased platelet aggregation. However, platelet adhesiveness has not been systematically explored in VTE patients. Objectives To evaluate platelet adhesive functions in VTE patients. Methods Platelet adhesion was evaluated by using whole blood samples from VTE patients, selected based on short closure times on the PFA-100 ( n = 54), and matched healthy individuals ( n = 57) in: (i) the PFA-100, (ii) a cone plate analyzer (CPA), on a plastic surface, (iii) microfluidic devices, with two- and three-dimensional evaluation, and (iv) membrane glycoprotein analysis. Intraplatelet signaling was evaluated in isolated collagen type I (Col-I) activated platelets and platelets adhered on Col-I or von Willebrand factor (VWF) coated coverslips under flow. VWF antigen and ADAMTS-13 activity were measured in plasma samples. Results PFA-100 closure times remained significantly shorter in patients. The CPA test showed a significant increase in the platelet aggregates size when using blood from VTE patients. Platelet adhesion on Col-I revealed a higher area covered by platelets and increased aggregate volume when exposed to samples from VTE patients. Protein P-ZAP70/SYK72 showed a phosphorylation level significantly increased in patients' platelets. Plasma VWF was significantly elevated in VTE patients. Conclusions Platelets from VTE patients exhibit a proadhesive phenotype under flow conditions potentially related to the shortened occlusion times with the PFA-100. This enhanced adhesiveness may be explained by higher intraplatelet ZAP70/SYK72 phosphorylation and increased plasma VWF in patients. Therefore, primary hemostasis plays a significant role in the pathophysiology of VTE.

Keywords: closure times; intraplatelet protein; platelet adhesiveness; platelet aggregation; venous thromboembolism.

Grants and funding

Funding Grants PI 12/000612, PI 18/00434, and PI 21/01772 from Spanish Ministerio de Ciencia, Innovación y Universidades. CIBERER and CIBERCV are initiatives of ISCIII, co-financed by the European Regional Development Fund (ERDF), “A way to build Europe.” This study was also partially supported by PI19/00888 (Instituto de Salud Carlos III, ISCIII, cofinanciado por la Unión Europea); Ayuda (grant) 2021-SGR-01118, Agencia de Gestió de Ajuts Universitaris i de Recerca (AGAUR), Generalitat de Catalunya; Deutsche José Carreras Leukämie-Stiftung (23R/2021); and Fundació Marató de TV3 (202026-10).